An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of siltuximab in
participants with relapsed (the return of a disease or the signs and symptoms of a disease
after a period of improvement.) or refractory (cancer that does not respond to treatment)
multiple myeloma (a type of cancer that begins in plasma cells [white blood cells that
produce antibodies]).